Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 21, 2007, Pages 5978-5982

  Pannala, Madhavi ^a   Kher, Sunil ^a   Wilson, Norma ^a   Gaudette, John ^a   Sircar, Ila ^a   Zhang, Shao Hui ^a   Bakhirev, Alexei ^a   Yang, Guang ^a   Yuen, Phoebe ^a   Gorcsan, Frank ^a   Sakurai, Naoki ^a   Barbosa, Miguel ^a   Cheng, Jie Fei ^a  

^a Tanabe Research Laboratories   (United States)

Author keywords

EGFR inhibitor; Quinoline 3 carbonitrile

Indexed keywords

4 (CYCLOPROPYLAMINO)QUINOLINE 3 CARBONITRILE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PELITINIB; UNCLASSIFIED DRUG;

ARTICLE; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYMATIC ASSAY; STRUCTURE ACTIVITY RELATION;

ENZYME INHIBITORS; NITRILES; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548833037     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.07.071     Document Type: Article

References (14)

1. Herbestt R.S. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 21-26
2. Baselga J., and Arteaga C.L. J. Clin. Oncol. 23 (2005) 2445
3. Kamath S., and Buolamwini J.K. Med. Res. Rev. 26 (2006) 569
4. Fujino S., Enokibori T., and Tezuka N. Eur. J. Cancer 32A (1996) 2070-2074
5. Speake G., Holloway B., and Costello G. Curr. Opin. Pharmacol. 5 (2005) 343-349
6. Rabindran S.K. Cancer Lett. 227 (2005) 9-23
7. Grunwald V., and Hidalgo M. J. Natl. Can. Inst. 95 (2003) 851
8. Harari P.M. Endocr. Relat. Cancer 11 (2004) 689-708
9. Wissner A., Berger D.M., Boschelli D.H., Floyd M.B., Greenberger L.M., Gruber B.C., Johnson B.D., Mamuya N., Nilakatan R., Reich M.F., Shen R., Tsou H.R., Upeslacis E., Wang Y.F., Wu B., Ye F., and Zhang N. J. Med. Chem. 43 (2000) 3244-3256
10. Boschelli D.H., Ye F., Wang Y.D., Dutia M., Johnson S.L., Wu B., Miller K., Powell D.W., Yaczko D., Young M., Tischler M., Arndt K., Discafani C., Etienne C., Gibbons J., Grod J., Lucas J., Weber J.M., and Boschelli F. J. Med. Chem. 44 (2001) 3965-3977
11. Wissner A., Overbeek E., Reich M.F., Floyd M.B., Johnson B.D., Mamuya N., Rosfjord E.C., Discafani C., Davis R., Shi X., Rabindran S.K., Gruber B.C., Ye F., Hallett W.A., Nilakantan R., Shen R., Wang Y.-F., and Greenberger L.M.H.-R. J. Med. Chem. 46 (2003) 49-63
12. Meyer O.G.J., Frohlich R., and Haufe G. Synthesis 10 (2000) 1479-1490
13. v-src peptide, 1% DMSO, and 0.0098-10 μM testing compound. Assays were initiated with the addition of the ATP substrate. Data were fitted to the Dixon competitive inhibition equation using Grafit 5.0 (Erithacus Software).
14. Cell-based EGFR autophosphorylation (Y1068) was performed with A431 cells in a 96-well format. Briefly, A431 cells (60,000 per well) were incubated at 37 °C overnight in 200 μL of Dulbecco's Modified Eagle's Medium (DMEM, GIBCOBRL, Cat#11995-073) containing 10% FBS. After removal of the medium, EGFR inhibitor in 100 μL DMEM was added and incubated for 60 min at 37 °C. Human EGF (40 ng/well) in DMEM was added and incubated for additional 20 min. Routine wash and 60 μL PIPA-2 buffer were added to lyse the cells. After centrifugation, the supernatant of the cell lysates was detected with ELISA kit for pY1068 according to the manufacturer's instruction (Biosource).